Dr. Alexander Eaton presents on development of new Guarded Injection Device at American Association of Ophthalmology Meeting

Dr. Alexander M. Eaton will present on the development of a new device designed to improve the safety and comfort of patients during intravitreal injections at the annual meeting of the American Association of Ophthalmology in Chicago on Saturday, Nov. 10. Eaton will share results of clinical use of the Guarded Injection Device following clinical trials at Retina Health Center involving 67 patients.

The device was developed by Eaton in collaboration with Dr. Hussein Wafapoor of Retina Health Center, Dr. Robert Avery of California Retina Consultants, and former Alcon employees Dave Booth and Dyson Hickingbotham. The device incorporates a small gauge needle covered by a thin protective sleeve designed to protect the needle from contamination risks before and during the injection such as aerosolized saliva droplets from speech or breathing, as well as from the eyelashes or other external contaminants. Retina Health Center recently began clinical trials to evaluate if the device is faster and/or more comfortable than existing techniques that use a lid speculum.

This is the first of a number of products being developed by I-Tech JV Development Company which address issues with intravitreal injections to reach clinical trial. By combining a team of retinal thought leaders and experienced device designers, the I-Tech JV Development Company is able to rapidly assess and develop products to meet evolving retina needs. 

Tags:

About Us

Established in 1992 by Teri Hansen, APR, Priority Marketing is a full-service marketing, advertising and public relations agency with a reputation for achieving results.

Quick facts

Dr. Alexander Eaton presents on development of new Guarded Injection Device at American Association of Ophthalmology Meeting
Tweet this
Dr. Alexander M. Eaton will present on the development of a new device designed to improve the safety and comfort of patients during intravitreal injections at the annual meeting of the American Association of Ophthalmology in Chicago on Saturday, Nov. 10. Eaton will share results of clinical use of the Guarded Injection Device following clinical trials at Retina Health Center involving 67 patients. The device was developed by Eaton in collaboration with Dr. Hussein Wafapoor of Retina Health Center, Dr. Robert Avery of California Retina Consultants, and former Alcon employees Dave Booth and Dyson Hickingbotham. The device incorporates a small gauge needle covered by a thin protective sleeve designed to protect the needle from contamination risks before and during the injection such as aerosolized saliva droplets from speech or breathing, as well as from the eyelashes or other external contaminants. Retina Health Center recently began clinical trials to evaluate if the device is faster and/or more comfortable than existing techniques that use a lid speculum. This is the first of a number of products being developed by I-Tech JV Development Company which address issues with intravitreal injections to reach clinical trial. By combining a team of retinal thought leaders and experienced device designers, the I-Tech JV Development Company is able to rapidly assess and develop products to meet evolving retina needs.
Tweet this
Eaton will share results of clinical use of the Guarded Injection Device following clinical trials at Retina Health Center involving 67 patients.
Tweet this